NLS Pharmaceutics Analyst Ratings
NLS Pharmaceutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/06/2022 | 991.11% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 2082.21% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 1354.81% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 09/06/2022 | 991.11% | Laidlaw & Co. | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 12 月 3 日 | 2082.21% | 布鲁克林资本 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 03/03/2021 | 1354.81% | Maxim 集团 | → 8 美元 | 启动覆盖范围开启 | → 购买 |
NLS Pharmaceutics Questions & Answers
NLS 药学问题与解答
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Laidlaw & Co. on September 6, 2022. The analyst firm set a price target for $6.00 expecting NLSP to rise to within 12 months (a possible 991.11% upside). 1 analyst firms have reported ratings in the last year.
莱德劳公司于2022年9月6日公布了NLS Pharmacetics（纳斯达克股票代码：NLSP）的最新目标股价。该分析公司将目标股价定为6.00美元，预计NLSP将在12个月内升至12个月内（可能上涨991.11％）。1家分析公司去年公布了评级。
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Laidlaw & Co., and NLS Pharmaceutics initiated their buy rating.
Laidlaw & Co. 提供了NLS Pharmacetics（纳斯达克股票代码：NLSP）的最新分析师评级，NLS Pharmacetics启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on September 6, 2022 so you should expect the next rating to be made available sometime around September 6, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与NLS Pharmacetics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。NLS Pharmacetics的最新评级是在2022年9月6日发布的，因此您应该预计下一个评级将在2023年9月6日左右公布。
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a initiated with a price target of $0.00 to $6.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.55, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的NLS Pharmacetics（NLSP）评级已启动，目标股价为0.00美元至6.00美元。NLS Pharmacetics（NLSP）目前的交易价格为0.55美元，在分析师的预测区间内。